Business
Spectral Diagnostics contributes to the first International Sepsis Forum Biomarker Conference
Spectral Diagnostics contributes to the first International Sepsis Forum Biomarker Conference.
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\n\nTORONTO, Nov. 7 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) today\nannounced its role as a major partner in the International Sepsis Forum (ISF)\nBiomarker Conference recently held in Toronto, Canada. The main goal of the\nconference was to draft consensus recommendations for the inclusion of certain\nbiomarkers into mainstream clinical practice in patients with sepsis.\nBiomarkers have proven to be very useful in clinical situations such as heart\nattack and congestive heart failure. This conference is the first to focus on\nsepsis biomarkers and incorporating them into clinical practice.\nDr. Paul Walker, MD, CEO of Spectral stated, \"It has been a great honor\nto take a significant role at this meeting. The ISF recommendations will help\nshape the future of sepsis diagnosis and treatment. The measurement of\nendotoxin continues to be a leading candidate to be widely adopted into\nclinical practice for patients with suspected sepsis. The importance of\nendotoxin measurement continues to grow as more clinicians recognize the added\nvalue of measuring endotoxin in critically ill patients and with the emergence\nof major pharmaceutical trials directly targeting endotoxin in the\nbloodstream.\" Spectral's Endotoxin Activity Assay (EAA(TM)) provides\nphysicians the ability to rapidly and accurately determine endotoxin levels in\na critically ill patient.\nThe International Sepsis Forum (ISF) seeks to improve the understanding\nand clinical management of patients with severe sepsis through workshops,\nlectures, debates, practice guidelines, and training programs for\nprofessionals worldwide. The ISF is a partnership of leading global experts\nand industry partners in the sepsis area. Severe sepsis is one of the most\nsignificant challenges in critical care. Each year, more than 750,000 people\nin the U.S. will develop severe sepsis, and more than 215,000 will die from\nthe condition. Treating patients with severe sepsis costs U.S. hospitals\nnearly $17 billion a year.\n\"This ISF conference reaffirms the value of Spectral's EAA(TM) program.\nSpectral's strategy of continuing clinical promotion with the most important\nthought leaders and academic centers in critical care, together with ongoing\nstudies aimed at expanding the EAA(TM) into other critical disease areas such\nas renal failure, burns, trauma, and transplantati...